SuccarLSulaicaEMDonahueKRWanatMA. Management of anticoagulation with impella(r) percutaneous ventricular assist devices and review of new literature. J Thromb Thrombolysis. 2019;48(2):284-291.
2.
AllenderJEReedBNFosterJL, et al. Pharmacologic considerations in the management of patients receiving left ventricular percutaneous mechanical circulatory support. Pharmacotherapy. 2017;37(10):1272-1283.
3.
Abiomed Inc. Dextrose with Heparin as Default Impella Purge Solution. Danvers MA: Abiomed Inc.2015.
4.
ReedBNDiDomenicoRJAllenderJE, et al. Survey of anticoagulation practices with the impella percutaneous ventricular assist device at high-volume centers. J Interv Cardiol. 2019;2019:3791307.
5.
NewsomeASTaylorAGarnerS. Anticoagulation of a percutaneous left ventricular assist device using a low-dose heparin purge solution protocol: a case series. J Pharm Pract. 2019;33(4):471-476.
6.
BowersRDNowakJBryanDBiondiNDorsettB. Utilization of a dextrose-only purge solution for an lvad in patients with suspected hit: a case series [published ahead of print Jun 26 2020]. J Pharm Pract. doi:10.1177/0897190020934304.
7.
ISMP. High-alert medication feature: anticoagulant safety takes center stage in 2007. ISMP. Accessed February 23, 2021.
8.
JiangCStuartMMakowskiCJenningsDLToL. Safety and efficacy of a percutaneously inserted ventricular support device purge solution heparin 25 U/mL. Ann Pharmacother. 2021;55(2):174-180.
9.
DietrichJNKazmiH. Bleeding risks in patients on percutaneous ventricular assist devices receiving two different dextrose concentrations of heparinized purge solution: a case series. J Pharm Pract. 2019;32(4):464-469.
